Table 4.

In vitro anti-proliferative activity of compounds 5a-r and the anticancer drug Doxorubicin toward human prostate cancer (PC-3), colorectal carcinoma (HCT-116), hepatocellular carcinoma (HepG-2), epithelioid cervical carcinoma (HeLa) and mammary gland breast cancer (MCF-7) cell lines.

Comp. No	X	Ar	IC50 (µM)a
			PC-3	HCT-116	HepG-2	HeLa	MCF-7
5a	H	C6H5	67.26 ± 3.6	59.23 ± 3.3	48.32 ± 2.9	41.81 ± 2.4	51.26 ± 2.9
5b	H	4-ClC6H4	87.82 ± 4.1	85.51 ± 4.4	65.29 ± 3.4	71.48 ± 3.7	78.62 ± 3.9
5c	H	4-BrC6H4	78.97 ± 3.9	80.25 ± 4.2	56.43 ± 3.2	83.86 ± 4.0	72.31 ± 3.7
5d	H	4-CH3C6H4	53.19 ± 2.9	58.63 ± 3.2	38.24 ± 2.5	49.83 ± 2.7	45.66 ± 2.6
5e	H	4-CH3OC6H4	12.85 ± 1.0	11.96 ± 0.9	16.30 ± 1.4	9.87 ± 0.7	6.90 ± 0.4
5f.	H	2-Naphthyl	> 100	94.26 ± 4.8	81.62 ± 4.2	> 100	86.49 ± 4.4
5g	F	C6H5	16.73 ± 1.3	28.27 ± 2.1	20.87 ± 1.6	30.67 ± 2.1	19.64 ± 1.4
5h	F	4-ClC6H4	23.56 ± 1.9	39.74 ± 2.5	22.07 ± 1.8	18.11 ± 1.5	32.78 ± 2.2
5i	F	4-BrC6H4	> 100	> 100	88.57 ± 4.5	> 100	91.18 ± 4.8
5j	F	4-CH3C6H4	90.04 ± 4.6	73.86 ± 3.9	70.28 ± 3.8	52.53 ± 2.9	66.28 ± 3.5
5k	F	4-CH3OC6H4	9.71 ± 0.8	6.47 ± 0.5	11.27 ± 0.9	7.09 ± 0.5	3.51 ± 0.2
5l	F	2-Naphthyl	> 100	89.05 ± 4.5	77.21 ± 4.0	93.62 ± 4.7	84.03 ± 4.3
5m	Cl	C6H5	33.59 ± 2.2	36.42 ± 2.3	29.53 ± 2.2	21.59 ± 1.8	26.04 ± 1.9
5n	Cl	4-ClC6H4	40.70 ± 2.4	46.11 ± 2.6	31.98 ± 2.3	25.65 ± 2.0	39.21 ± 2.5
5o	Cl	4-BrC6H4	61.39 ± 3.4	24.50 ± 1.8	47.38 ± 2.8	15.28 ± 1.2	13.72 ± 1.2
5p	Cl	4-CH3C6H4	55.86 ± 3.1	62.79 ± 3.5	43.65 ± 2.7	37.26 ± 2.3	57.39 ± 3.2
5q	Cl	4-CH3OC6H4	42.08 ± 2.6	17.58 ± 1.4	35.18 ± 2.5	10.49 ± 0.9	8.53 ± 0.7
5r	Cl	2-Naphthyl	75.45 ± 3.8	68.35 ± 3.7	51.79 ± 3.1	56.40 ± 3.3	63.54 ± 3.4
Doxorubicin			8.87 ± 0.6	5.23 ± 0.3	4.50 ± 0.2	5.57 ± 0.4	4.17 ± 0.2

^aIC₅₀ Values presented as the mean ± SD of three separate determinations.

Significant values are in bold.